Veterinary Oncologist Dr. Gregory K. Ogilvie to lead clinical study
SAN DIEGO, May 31,2012 -- Genelux Corporation, a privately-held clinical-stage biopharmaceutical company focused on development and commercialization of best–in-class vaccinia virus based oncolytic viral therapies and companion diagnostics for human cancer patients, today announced the start of a ground-breaking clinical study involving the oncolytic Vaccinia virus V-VET1 in canine cancer patients with various measurable malignancies. Although oncolytic viruses are being more extensively evaluated in humans, this study is the first of its kind ever reported in dogs, and will evaluate the safety, dosing and efficacy of V-VET1, a veterinary-use, intravenously-delivered oncolytic Vaccinia virus.
“V-VET1 is a specially-designed veterinary product candidate that has shown encouraging safety and efficacy results in preclinical studies against a number of cancers afflicting dogs, including Canine Soft Tissue Sarcoma,” said Dr. Aladar Szalay, Founder and CEO of Genelux Corporation.” It is based on Genelux Corporation’s proprietary product platform that potentially can deliver both therapeutic and diagnostic constructs directly to tumors without harming healthy tissues or cells. We are very pleased to be working with a world- renowned Veterinary Oncologist and Internal Medicine specialist like Dr. Gregory Ogilvie to assess V-VET1 in dogs.“
“This is a tremendously exciting time in veterinary oncology as novel therapies like V-VET1 have the potential fundamentally to change the way veterinarians treat companion animals with advanced cancer,” says Dr. Gregory K. Ogilvie, DVM, study Principal Investigator and Director of the CVS Angel Care Cancer Center in Carlsbad, California. “This novel therapy has the potential selectively to kill tumors and metastases while sparing our beloved canine patients the many negative side effects of conventional therapies like chemo and radiation”.
Canine clinical studies also have potentially broader applicability. Dr. Ogilvie, who has spent many years in translational medicine adds, “Companion animal clinical study results often translate in important ways to pediatric clinical trials. The similarities in the way certain canine cancers like osteosarcoma, for example, develop and behave, are nearly identical to those in pediatric patients. It is our hope that, in addition to helping our companion animals, this study can eventually serve also as the basis for additional important studies in pediatric cancer patients.”
The open-label dose-escalation study will be conducted on site at California Veterinary Specialists (CVS) Angel Care Cancer Center, based in Carlsbad, California. For additional information, please visit www.cvsangelcare.com.
V-VET1 is a genetically characterized, veterinary-grade replication-competent oncolytic vaccinia virus-based therapy derived from the LIVP vaccinia virus strain. It is systemically administered to deliver a multi-pronged attack on cancer: 1) V-VET1 selectively enters and lyses (kills) cancer cells through replication and amplification within cancer cells, causing cells to rupture and viral progeny to infect neighboring cancer cells; 2) tumor vasculature is destroyed during this process, reducing significantly the blood supply that enables tumors to grow; and 3)) the oncolytic process stimulates innate and adaptive immune responses resulting in tumor rejection (similar to immune-mediated tissue-specific destruction). Future derivatives of V-VET 1 can potentially carry and over-express therapeutic, deep tissue imaging, or immuno-modulatory genes for production within the tumor.
About CVS Angel Care Cancer Center
The California Veterinary Specialists (CVS) Angel Care Cancer Center, based in Carlsbad, California is a comprehensive group within the CVS specialty/critical care hospitals that provides direct care for companion animal patients with cancer and their families. CVS offers the most innovative clinical research, diagnostics and treatments available to fight against cancer. The Angel Care Cancer Center specializes in Medical oncology, Radiation Oncology/Diagnostic Imaging, Surgical Oncology and Emergency and Critical Care, and offers some of the most experienced and highly trained board certified veterinary medical professionals and state of the art facilities in the world
About Genelux Corporation
Genelux Corporation was founded in 2001 with a mission to develop safe and effective diagnostic and therapeutic solutions for cancer and inflammatory diseases for which there are no effective treatments today. Genelux Corporation is headquartered in San Diego, California. For additional information, please visit www.genelux.com.
Genelux Forward Looking Statement
Statements made about Genelux Corporation, other than statements of historical fact, reflect Management’s current beliefs and assumptions founded on the data and information currently available to us. Statements of the company’s progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, patents, inception and/or continuation of corporate and other strategic partnerships and the need for additional funding or financing.
A few weeks back, a black-and-white terrier mix named Chance entered a clinical trial for a drug that may offer a completely new way to combat cancer—not only in dogs, but in people, too. The drug, made by San Diego-based Genelux, uses a genetically engineered virus to annihilate tumor cells. Genelux made two different versions of the drug and is now testing one in people and other in dogs, as part of a wide-ranging research strategy designed to yield cutting-edge cancer treatments for both man and man’s best friend. Why dogs? “Cancer as a
Come join us on Saturday, February 22, and support the San Diego K9 Cancer Walk Benefiting Morris Animal Foundation to help find a cure. California Veterinary Specialists will be there in full support of the Morris Foundation and will have a team walking as well. Our team name is Angel Care for the Cure and our Team Capitan is Leah Larscheidt. Please help support our team by joining us for the walk, donating to our team or just coming out to cheer us on. We hope to see you there!
Investigators from California Veterinary Specialists empowered by funding from the Special Care Foundation for Companion Animals, has worked with the discovery team led by Dr. Genevieve Hansen to develop a novel therapy for T-cell lymphoma in dogs. The veterinary oncologists and nurses at all three CVS hospitals (Murrieta, Ontario and Carlsbad) executed a series of clinical and basic science trials to document the safety and efficacy of the monoclonal antibody therapy that triggers the immune system to kill the T cell lymphoma cancer cells ...
We are in a process developing a new therapy for dogs with lymphoma that harnesses the immune system to destroy its own cancer. With appropriate therapy we are able to not only enhance and improve their quality of life but also extend that life and reduce the need for chemotherapy. This non-invasive, fully-funded study is one in which we take animals that have lymphoma and willing families who are excited about exploring new opportunities that will enhance and improve the quality of life of a pet with cancer. The veterinary health team...
Inclusion Criteria: Clinically healthy dogs with palpable, measurable cyto- or histologically confirmed malignancy and acceptable recent chest radiographs and blood work. Study will cover costs of each drug signal therapy delivered by a device that is placed over the palpable 1-6 cm tumor and all in-hospital rechecks and restaging at CVS.